The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall survival and patterns of care for women with rare ovarian cancers: A prospective study from the Australian National Gynae-Oncology Registry (NGOR).
 
Mahendra Naidoo
Travel, Accommodations, Expenses - AstraZeneca
 
Clare L. Scott
Consulting or Advisory Role - Oncology One
Research Funding - AstraZeneca; Boehringer Ingelheim (Inst); Eisai; IDEAYA Biosciences (Inst)
Patents, Royalties, Other Intellectual Property - Royalty agreement for venetoclax (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Illumina; MSD
(OPTIONAL) Uncompensated Relationships - AstraZeneca; GlaxoSmithKline; MSD Oncology
 
Orla McNally
No Relationships to Disclose
 
Rob Rome
No Relationships to Disclose
 
Sharnel Perera
No Relationships to Disclose
 
Yeh Chen Lee
Speakers' Bureau - AstraZeneca
Research Funding - BeiGene (Inst)
 
Aleesha Whitely
No Relationships to Disclose
 
Michael Burling
No Relationships to Disclose
 
Lyndal Anderson
No Relationships to Disclose
 
Paul Cohen
Employment - St John of God Healthcare
Stock and Other Ownership Interests - Clinic IQ
Honoraria - AstraZeneca
Consulting or Advisory Role - Clinic IQ
Research Funding - ANZGOG; St John of God Foundation
 
Gary Edward Richardson
Research Funding - Adagene (Inst); Agenus (Inst); AstraZeneca (Inst); BeiGene (Inst); Bio-Thera Solutions (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CBT Pharmaceuticals (Inst); ChemoCentryx (Inst); Corvus Pharmaceuticals (Inst); Curon Biopharmaceutical (Inst); D3 Bio (Inst); Eucure Biopharma (Inst); Five Prime Therapeutics (Inst); Fosun Pharma (Inst); Gene Quantum (Inst); Genfleet Therapeutics (Inst); ImmunGen Inc (Inst); Imugene (Inst); InventisBio (Inst); Janssen Oncology (Inst); Keythera Pharmaceuticals (Inst); LaNova Australia (Inst); Medicenna (Inst); Merck (Inst); Minghui Pharmaceutical (Inst); Neoleukin Therapeutics (Inst); Novotech (Inst); Pfizer (Inst); PharmAbcine (Inst); RemeGen (Inst); Roche/Genentech (Inst); Seagen (Inst); Senz Oncology (Inst); Shanghai Henlius Biotech (Inst); Shanghai Henlius Biotech (Inst); Surface Oncology (Inst); Suzhou Alphamab (Inst); Takeda (Inst); Therapim (Inst); Zentalis (Inst)
 
Michael Friedlander
Honoraria - AstraZeneca; GlaxoSmithKline; MSD; Novartis
Consulting or Advisory Role - Abbvie; AstraZeneca; Eisai; Gilead Sciences; GlaxoSmithKline; Incyclix Bio; Lilly; MSD; Novartis; Takeda
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; MSD Oncology
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Novartis (Inst)
 
Alison Brand
No Relationships to Disclose
 
Simon Hyde
Stock and Other Ownership Interests - Cleo diagnostics
 
Michael Bunting
No Relationships to Disclose
 
Tom Jobling
Other Relationship - Board member- Cleo Diagnostics Ltd
 
John Raymond Zalcberg
Leadership - ICON Group; Lipotek
Stock and Other Ownership Interests - Amarin Corporation; Biomarin; CSL Limited; CSL Limited; Frequency Therapeutics; Gilead Sciences; Korro; Moderna Therapeutics; Novavax; Opthea; Orphazyme; UniQure
Consulting or Advisory Role - 1Globe Health Institute; Alloplex Biotherapeutics Inc; Deciphera; FivePHusion; Genor BioPharma; Merck Sharp & Dohme; NOUS Group; Novotech; Oncology Republic; Revolution Medicines; Specialised Therapeutics
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); IQvia (Inst); Medtronic (Inst); MSD Oncology (Inst); Mylan (Inst); Pfizer (Inst); Servier (Inst); Taiho Oncology (Inst)
Travel, Accommodations, Expenses - ICON Group; MSD Oncology; Praxis Therapeutics